These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 38572025)

  • 1. The Significance of Eosinophil-to-Lymphocyte Ratio in Predicting Response to Omalizumab Treatment in Patients with Bullous Pemphigoid: A Case Series.
    Akin G; Avci C; Akarsu S
    Indian J Dermatol; 2024; 69(1):81-85. PubMed ID: 38572025
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rapid Disease Control in First-Line Therapy-Resistant Mucous Membrane Pemphigoid and Bullous Pemphigoid with Omalizumab as Add-On Therapy: A Case Series Of 13 Patients.
    Alexandre M; Bohelay G; Gille T; Le Roux-Villet C; Soued I; Morin F; Caux F; Grootenboer-Mignot S; Prost-Squarcioni C
    Front Immunol; 2022; 13():874108. PubMed ID: 35514989
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Omalizumab for the Treatment of Bullous Pemphigoid: A Systematic Review of Efficacy and Safety.
    D'Aguanno K; Gabrielli S; Ouchene L; Muntyanu A; Ben-Shoshan M; Zhang X; Iannattone L; Netchiporouk E
    J Cutan Med Surg; 2022; 26(4):404-413. PubMed ID: 35379011
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Omalizumab therapy for bullous pemphigoid.
    Yu KK; Crew AB; Messingham KA; Fairley JA; Woodley DT
    J Am Acad Dermatol; 2014 Sep; 71(3):468-74. PubMed ID: 24954907
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The significance of eosinophil and eosinophil lymphocyte ratio (ELR) in predicting response to omalizumab treatment in patients with severe allergic asthma.
    Özgen H; Tepetam FM; Bulut İ; Örçen C
    Tuberk Toraks; 2021 Mar; 69(1):39-48. PubMed ID: 33853304
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Successful Treatment of a Bullous Pemphigoid Patient with Rituximab Who Was Refractory to Corticosteroid and Omalizumab Treatments.
    Bilgiç Temel A; Bassorgun CI; Akman-Karakaş A; Alpsoy E; Uzun S
    Case Rep Dermatol; 2017; 9(1):38-44. PubMed ID: 28413387
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of Omalizumab on FcεRI and IgE Expression in Lesional Skin of Bullous Pemphigoid.
    Seyed Jafari SM; Gadaldi K; Feldmeyer L; Yawalkar N; Borradori L; Schlapbach C
    Front Immunol; 2019; 10():1919. PubMed ID: 31474990
    [TBL] [Abstract][Full Text] [Related]  

  • 8. IgE blockade in autoimmunity: Omalizumab induced remission of bullous pemphigoid.
    James T; Salman S; Stevenson B; Bundell C; Kelly G; Nolan D; John M
    Clin Immunol; 2019 Jan; 198():54-56. PubMed ID: 30557620
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Case Report: Combination of Omalizumab and Dupilumab for Recalcitrant Bullous Pemphigoid.
    Seyed Jafari SM; Feldmeyer L; Bossart S; Simon D; Schlapbach C; Borradori L
    Front Immunol; 2020; 11():611549. PubMed ID: 33584689
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Research progress of omalizumab in the treatment of bullous pemphigoid.
    Ling X; Shou X; Lou Y; Ling J; Zhang M; Yu T; Gu W
    J Dermatol; 2023 May; 50(5):575-587. PubMed ID: 36971190
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Omalizumab as an alternative therapeutic tool in the treatment of bullous pemphigoid: A case report.
    Vico-Alonso C; Calleja-Algarra A; Aragón-Miguel R; Sánchez-Velázquez A; Velasco-Tamariz V; Ortiz-Romero PL; Monsálvez-Honrubia V
    Dermatol Ther; 2019 Mar; 32(2):e12829. PubMed ID: 30659716
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [EFFECTIVE TREATMENT FOR BULLOUS PEMPHIGOID WITH OMALIZUMAB].
    Neumark M; Tal Y; Zlotogorski A; Molho-Pessach V
    Harefuah; 2020 Jan; 159(1):29-30. PubMed ID: 31930804
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of omalizumab for the treatment of bullous pemphigoid: Spanish multicentre real-world experience.
    Aguado Vázquez Á; Estébanez Corrales A; Melgosa Ramos FJ; Mascaró Galy JM; Fulgencio-Barbarin J; Bosch Amate X; Curto Barredo L; Blanes-Martínez M; Ruiz-Villaverde R; Ballester Martínez A; Martín-Torregrosa D; Castaño Fernández JL; Cabeza Martínez R; Pérez-Ferriols A; Ramos Rodríguez D; Boix Vilanova J; Melé-Ninot G; Expósito Serrano V; España Alonso A; Mateu-Puchades A
    Clin Exp Dermatol; 2024 Aug; 49(9):1002-1006. PubMed ID: 38430106
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Successful treatment of bullous pemphigoid with omalizumab as corticosteroid-sparing agent: report of two cases and review of literature.
    Balakirski G; Alkhateeb A; Merk HF; Leverkus M; Megahed M
    J Eur Acad Dermatol Venereol; 2016 Oct; 30(10):1778-1782. PubMed ID: 27357866
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Omalizumab as a corticosteroid-sparing agent in the treatment of bullous pemphigoid.
    Vassallo C; Somenzi A; De Amici M; Barruscotti S; Brazzelli V
    Dermatol Ther; 2022 Dec; 35(12):e15946. PubMed ID: 36259470
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predictors of response to therapy with omalizumab in patients with severe allergic asthma - a real life study.
    Kallieri M; Papaioannou AI; Papathanasiou E; Ntontsi P; Papiris S; Loukides S
    Postgrad Med; 2017 Aug; 129(6):598-604. PubMed ID: 28427296
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunoglobulin E and bullous pemphigoid.
    Cozzani E; Gasparini G; Di Zenzo G; Parodi A
    Eur J Dermatol; 2018 Aug; 28(4):440-448. PubMed ID: 30325326
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of the Patients with Chronic Urticaria Who Responded and Did Not Respond to Omalizumab Treatment: A Single-Center Retrospective Study.
    Cakmak ME
    Int Arch Allergy Immunol; 2022; 183(11):1209-1215. PubMed ID: 36007494
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-IgE monoclonal antibody (omalizumab) is effective in treating bullous pemphigoid and its effects on soluble CD200.
    Yalcin AD; Genc GE; Celik B; Gumuslu S
    Clin Lab; 2014; 60(3):523-4. PubMed ID: 24697134
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of Omalizumab in Patients with Chronic Spontaneous Urticaria and Its Association with Serum IgE Levels and Eosinophil Count.
    Tamer F; Gulru Erdogan F; Dincer Rota D; Yildirim D; Akpinar Kara Y
    Acta Dermatovenerol Croat; 2019 Jun; 27(2):101-106. PubMed ID: 31351504
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.